Empagliflozin 10 MG ( DrugBank: Empagliflozin )


2 diseases
IDDisease name (Link within this page)Number of trials
58Hypertrophic cardiomyopathy1
97Ulcerative colitis1

58. Hypertrophic cardiomyopathy


Clinical trials : 126 Drugs : 135 - (DrugBank : 42) / Drug target genes : 46 - Drug target pathways : 162
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05182658
(ClinicalTrials.gov)
June 1, 202221/12/2021Empagliflozin in Hypertrophic CardiomyopathyThe Use of Empagliflozin in Patients With Hypertrophic CardiomyopathyHypertrophic Cardiomyopathy;Heart FailureDrug: Empagliflozin 10 MG;Drug: PlaceboInstitute of Cardiology, Warsaw, PolandMedical University of Bialystok;University of Eastern Finland;Amsterdam UMC, location VUmcNot yet recruiting18 Years70 YearsAll250Phase 3Poland

97. Ulcerative colitis


Clinical trials : 2,630 Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05058417
(ClinicalTrials.gov)
October 1, 202116/9/2021Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative ColitisAssessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative ColitisUlcerative ColitisDrug: Empagliflozin 10 MG;Drug: PlaceboSadat City UniversityNULLRecruiting18 Years60 YearsAll50Phase 2Egypt